Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Capital Expenditures (2016 - 2025)

Macrogenics (MGNX) has disclosed Capital Expenditures for 14 consecutive years, with -$1.6 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 1716.0% to -$1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54000.0 through Dec 2025, down 46.0% year-over-year, with the annual reading at $54000.0 for FY2025, 46.0% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$1.6 million at Macrogenics, down from $426000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $4.7 million in Q3 2021, with the low at -$4.3 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $318368.4, with a median of $486000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures surged 843.49% in 2021, then plummeted 22572.73% in 2024.
  • Over 5 years, Capital Expenditures stood at -$4.3 million in 2021, then surged by 177.07% to $3.3 million in 2022, then crashed by 51.98% to $1.6 million in 2023, then plummeted by 93.74% to $100000.0 in 2024, then plummeted by 1716.0% to -$1.6 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$1.6 million, $426000.0, and $715000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.